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1. ABSTRACT 
Matriptase-2 (also known as TMPRSS6) is a recently identified member of the type II 
transmembrane serine protease family. Structurally this enzyme contains a short cytoplasmic amino 
terminal tail, a transmembrane region, a stem region containing two CUB domains and three LDL 
receptor class A domains, and at the carboxy terminal a trypsin-like serine protease domain. The 
matriptase-2 gene and encoded protein are highly conserved in mammals. Biochemically 
matriptase-2 has substrate specificity similar to the structurally related protein matriptase. Although 
the physiological function of matriptase-2 is not known, its high mRNA expression in liver and data 
from a limited number of studies indicating association with several cancers, it is likely that this 
enzyme will have important cell surface associated roles. Here we overview the identification of 
matriptase-2, summarise its structural features, biochemistry, expression pattern and disease 
associations and speculate on its potential functions.  
 
2. INTRODUCTION 
Proteolytic events at the cell surface regulate many important cellular processes requiring 
transduction of signals across the cell surface, release of bioactive growth factors, cytokines and 
peptides hormones, and interactions with other cells and basement membrane and extracellular 
matrix proteins. As these processes are associated with normal physiological responses such as 
inflammation and proliferation, and are also co-opted to facilitate progression of diseases such as 
cancer, it is critical that we have a clear understanding of the proteases involved in these processes 
and the mechanisms regulating the functions of these enzymes. 
 
Matriptase-2 (1, 2) is a  member of the type II transmembrane serine protease (TTSP) family; a 
recently recognised family of cell surface proteolytic enzymes (3-6). Structurally, the TTSPs are 
characterised by a short amino terminal cytoplasmic tail, a membrane spanning domain, a stem 
region containing modular protein interacting domains, a short pro-enzyme region and a carboxy 
 3
terminal trypsin-like serine protease domain. It is clear that each of the functionally characterised 
members of the TTSP family have significant roles in normal physiology and disease. For example, 
the heart expressed TTSP corin (7) activates pro-atrial natriuretic peptide to the active hormone 
critical for maintenance of blood pressure and salt-water balance (8). In addition, expression of the 
gene encoding the TTSP hepsin, originally identified in liver (9), is the most highly up-regulated 
gene in prostate cancer (10-14). Furthermore, transgenic studies in mice indicate that hepsin has a 
functional role in prostate cancer progression (15). Also, enteropeptidase, expressed on the surface 
of enterocytes, is the physiological activator of trypsinogen and thus essential in digestion (16). 
Studies in knock-out mice indicate that matriptase/MT-SP1 is required for postnatal survival, 
epidermal barrier function, hair follicle development, and thymic homeostasis (17), while 
expression of this TTSP in the skin of transgenic mice causes ras-independent multistage 
carcinogenesis and promotes ras-mediated malignant transformation (18). Fusions of the ETS 
transcription factor genes ERG and ETV1 with the promoter of the TTSP gene TMPRSS2 is a 
common occurrence in prostate cancer with the overexpression of these ETS family members 
driven by androgen-responsive elements within the TMPRSS2 promoter (19). TMPRSS2 expression 
is also upregulated in prostate cancer (20) and this enzyme activates the G protein coupled receptor, 
protease activated receptor 2, in prostate cancer cells (21). Furthermore, a role for TMPRSS2 in 
angiogenesis is suggested by the observation that TMPRSS2 expression is up-regulated in micro-
vascular endothelial cells undergoing three dimensional tubule morphogenesis (22). The non-
mammalian TTSP stubble-stubbloid is required for hormone-dependent epithelial morphogenesis of 
imaginal discs of Drosophila, including the formation of bristles, legs, and wings (23). Insertion of 
beta-satellite repeats into the TMPRSS3 gene causes both congenital and childhood onset autosomal 
recessive deafness (24). 
 
Although the roles of other TTSP family members have not been examined, the restricted 
expression patterns and method of identification of several of these enzymes are suggestive of 
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significant roles. For example, TMPRSS4 (formerly designated TMPRSS3) is overexpressed in 
pancreatic cancer (25), while the epithelial cell specific TTSP, DESC-1 (26, 27), is downregulated 
during squamous cell carcinoma progression and upregulated during normal epithelial 
differentiation (28). TMPRSS5, which is expressed in neuronal axons and at the synapses of 
motoneurons in the spinal cord, is thought to function at the surface of synapses to activate or 
inactivate other proteins (29). The human airway trypsin-like (HAT) TTSP, originally isolated from 
the sputum of patients with chronic airway diseases (30), has been proposed to have a role in these 
diseases because of the ability of this enzyme to mediate inflammatory responses such as increased 
mucus production (31) and TNFα activity (32). Other members of the TTSP family for which 
patho-physiological roles have not been determined include matriptase-3 (33), polyserase-I (34), 
MSPL (5, 35), DESC-2, DESC-3/HAT-like 1, MAT1, MAT2, HAT-like 2, HAT-like 3, HAT-like 
4, and HAT-like 5 (5, 26, 36, 37) and Xesp-2 from Xenopus laevis (38). 
 
3. IDENTIFICATION 
The matriptase-2 cDNA was identified in human (1) and mouse (2) using in silico approaches.  The 
complete human cDNA was cloned from fetal liver and named on the basis of its significant 
structural similarity to the TTSP matriptase (1). The mouse coding sequence was identified from an 
expressed sequence tag clone generated from adult liver (2). The rodent encoded proteins were 
originally designated Tmprss6 on the basis of TTSP nomenclature (2), however, for consistency the 
matriptase-2 designation is now applied across all species. The complete sequence of matriptase-2 
in macaque, dog and cow and a partial sequence in chimpanzee have also recently been deposited 
into sequence databases (Table 1). 
 
4. STRUCTURAL FEATURES AND BIOCHEMISTRY 
As shown in Figure 1 matriptase-2 has all the structural features of a TTSP including a short 
cytoplasmic amino terminal tail, a transmembrane region, a stem region containing two complement 
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protein subcomponents C1r/C1s, urchin embryonic growth factor and bone morphogenetic protein 1 
(CUB) domains and three low density lipoprotein receptor class A (LDLR) domains, and at the 
carboxy terminal a trypsin-like serine protease domain. These structural features are absolutely 
conserved across human, macaque, dog, cow, mouse and rat (Figure 2), with the human protein 
sharing 95.6% (775/811), 91.1% (739/811), 85.6% (694/811), 80.1% (650/811) and 80.4% 
(652/811) identity, respectively, to matriptase-2 from these species. Consistently, by Western blot 
analysis of lysates from transiently transfected cells, both human (1) and mouse (2) matriptase-2 
migrate close to the predicted molecular weight of ~90kDa. 
 
In addition to conserved structural domains, matriptase-2 contains conserved consensus N-
glycosylation sites and cysteine residues. Three consensus N-glycosylation sites are present within 
the region between the transmembrane domain and the first CUB domain. Three other sites occur 
within the second CUB domain and one within LDLR2. The lack of consensus N-glycosylation 
sites in the serine protease domain is in contrast to the majority of other TTSPs. However, HAT 
(30), Hepsin (9) , TMPRSS2 (20) and TMPRSS4 (25) also lack glycosylation in this region. 
Matriptase-2 also has a high content of cysteines - 37 extracellular cysteines are conserved in all 
species. On the basis of the crystal structure of the spermadhesin porcine seminal plasma (PSP)-I–
PSP-II heterodimer (39), cysteines C2/C3 and C4/C5 (numbering per Figure 2) form disulfide 
bonds in CUB1 and cysteines C6/C7 and C8/C9 within CUB2. Similarly, on the basis of the 
structure of the LDLR extracellular domain (40), cysteines C10/C12, C11/C14 and C13/C15 form 
disulfide bonds within LDLR1, C16/C18, C17/C20 and C19/C21 within LDLR2 and C22/C24, 
C23/C26 and C25/C27 within LDLR3. The following disulfide bonds form within the serine 
protease domain C29/C30, C32/C36, C33/C34 and C35/C37 and the pro and catalytic regions are 
linked by the C28/C31 pair. Finally, cysteine C1 of matriptase-2 is unpaired intramolecularly and 
therefore has the potential to form homo- or hetero- linkages (2).  
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As well as conserved disulfide bond forming cysteines, the matriptase-2 proteolytic domain has all 
the features common to members of the serine protease S1 family. These include the serine protease 
triad of 617H, 668D, and 762Ser residues (human numbering) required for catalytic activity, and an 
SWG motif predicted to be located at the top of the substrate S1 binding pocket positioning the 
scissile bond of the substrate in the correct orientation. Proteolytic activation of matriptase-2 is 
predicted to occur within a motif (576RIVGG) at the junction of the pro- and catalytic domains 
which is characteristic of serine proteases and conserved across species. Consistent with the 
presence of an aspartate residue, 6 amino acids before the catalytic serine, which specifies 
preference for trypsin-like serine protease cleavage following arginine or lysine residues, the 
recombinant matriptase-2 protease domain cleaves following arginine but not alanine. Interestingly 
and in contrast to the substrate specificity of the structurally similar TTSP matriptase (1, 41), the 
active recombinant matriptase-2 protease domain does not cleave following lysine (1). The authors 
explained this difference in peptide substrate specificity using a model of matriptase-2 based on the 
crystal structure of matriptase (42). Their analysis showed that matriptase residue 190S permits 
access of both arginine and lysine residues in the S1 pocket whereas an alanine at this position in 
matriptase-2 permits accommodation of arginine (1). Consistent with the serine protease 
classification of matriptase-2, its activity against tripeptide substrates was completely abolished by 
inhibitors of trypsin-like serine proteases (PMSF, AEBSF, leupeptin and aprotinin) but not by an 
inhibitor of chymotrypsin-like serine proteases (TPCK) or inhibitors of metallo (EDTA) or cysteine 
(E-64) proteases (1).  
 
Against macromolecular extracellular matrix (ECM) and basement membrane components, the 
recombinant matriptase-2 catalytic domain was able to cleave the ECM proteins fibronectin, 
fibrinogen and type I collagen in vitro but not the basement membrane protein laminin (1). In 
addition, the authors noted that matriptase-2 is not a bona fide collagenase as it did not generate the 
¾ and ¼ fragments typical of fibrillar collagenases. The matriptase-2 serine protease domain was 
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also incapable of activating the pro forms of the matrix metalloproteases MMP-2 or MMP-9 or the 
serine protease plasminogen, but was a low efficiency activator of pro-uPA (1). Interestingly, this 
domain which was generated in bacteria, was subject to autoactivation at 37°C, releasing the 
proteolytic region from its GST fusion (1). In contrast, in a mammalian cell system transiently over 
expressing mouse matriptase-2, there was no evidence by Western blot analysis under reducing 
conditions that the protease had been activated (2). This suggests that autoactivation of endogenous 
matriptase-2 may not be possible, potentially because the presence of the endogenous pro domain 
and stem region provide an inhibitory mechanism against auto-catalytic activity. Therefore, 
proteolytic activation of the matriptase-2 zymogen may represent a post-translation mechanism of 
controlling the catalytic activity of this TTSP.  
 
In addition to its defined structural domains, matriptase-2 also contains a region spanning residues 
83 to 186 (human numbering) which has low identity to sea urchin sperm protein, enteropeptidase, 
agrin (SEA) domains. In other SEA domain containing, membrane spanning proteins, 
autoproteolysis, following a glycine residue within a conserved motif (eg. GSVVV (43)), releases 
these molecules from the cell surface. Proteolysis within this conserved motif, which is located near 
the middle of the SEA domain, is catalysed by conformational stress and the hydroxyl of the serine 
present within the motif (43). Release from the cell surface by cleavage within a similar SEA 
domain motif has been reported for the TTSPs porcine enteropeptidase (44) and mouse 
matriptase/MT-SP1 (45) at the respective cleavage sites 117GSVIV and 149GSVIA. Another member 
of the TTSP family, HAT, contains a similarly located site (109GSGVR) within its SEA domain. In 
contrast the SEA domain-like region of matriptase-2 and the SEA domain of other TTSPs, such as 
mouse matriptase-3 (33) and DESC1 (26), lack a consensus cleavage site near the middle of the 
domain. However, the matriptase-2 SEA domain-like region contains a cleavage motif-like 
sequence (90GSLRV) proximal to its amino terminal whereas the mouse matriptase-3 SEA domain 
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has the sequence 201GSLQG near to its carboxy terminal. Whether cleavage within theses motifs 
mediates release of these TTSPs from the cell surface has not been examined.  
 
The role of each of these structural features in regulating matriptase-2 function has not yet been 
addressed. Clearly the cell surface location and orientation of matriptase-2, which have been 
confirmed for both the human (1) and mouse (2) proteins by confocal microscopy analysis of 
transiently transfected cells, provide a level of spatial regulation of the protease domain. It is also 
possible that the matriptase-2 cytoplasmic tail will modulate protein function. However, none of the 
matriptase-2 consensus phosphorylation sites are conserved across species, suggesting that 
phosphorylation of this protein is either not essential to its function or is unique to each organism. 
Furthermore, additional regulation of matriptase-2 activity will likely be achieved via its two CUB 
and three LDLR domains, and possibly also involve the region spanning the low-identity SEA 
domain. Each of these domains is common amongst TTSP family members (3-6) and, in particular, 
many CUB domain containing proteins are proteases (46). Accordingly, it will be of interest to 
determine whether the matriptase-2 CUB domains are involved in oligomerization or recognition of 
substrates as is the case for other proteins (46), and similarly, whether the LDLR domains of this 
TTSP mediate interactions with macromolecules such as serine protease:inhibitor complexes and 
lipoproteins (47). 
 
5. GENE STRUCTURE AND REGULATION 
As indicated in Figure 3, the matriptase-2 gene is highly conserved across mammalian species and 
ranges in size from ~29 kb in mouse to ~40 kb in chimpanzee. Each gene spans 18 exons with 17 
intervening introns, with the size and junctions of 14 of the exons absolutely conserved. Also, 
although the size of the last exon varies, the size of the coding sequence of this exon is conserved at 
159 nucleotides. Each of the mammalian matriptase-2 genes is located in a genomic region devoid 
of other TTSP genes. This is similar to other TTSP genes such as corin (7) and hepsin (48) and in 
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contrast to TMPRSS4 (25) and TMPRSS5 (29) which both localise to human chromosome region 
11q23.3, TMPRSS2 (49) and TMPRSS3 (24) to 21q22 and DESC2 and DESC3 to 4q11 (5). 
Sequences at the 5’ and 3’ end of each intron conform to the GT-AG rule for splice-site recognition 
(50) except for the 5’ end of the first human, chimpanzee and macaque intron which has GC instead 
of GT. All matriptase-2 protein domain boundaries correspond with intron/exon junctions of the 
encoding gene across all species (Figure 3A). The first CUB domain is encoded by two exons (7 
and 8), and the second CUB domain by three exons (9 to11). The three LDLR domains of 
matriptase-2 are each encoded by separate exons (12, 13 and 14). Finally, the serine-protease 
domain, including the pro region, is encoded by four exons (15 to 18).  
 
Variation occurs between lower and higher mammals towards the 5’ end of the matriptase-2 gene. 
In human, chimpanzee and macaque the initiating codon is located in exon 1 whereas in rodents this 
codon is in exon 2. The size of the intron interrupting the first two exons in these species is also 
different. In human, chimpanzee and macaque the first exon is only 95 nucleotides upstream of 
exon 2 whereas in rodents these exons are separated by an intron greater than 4.5 kb in size. At the 
protein level this variation appears to have little effect. As shown in Figure 2, the rodent protein 
extends 3 residues beyond the amino terminal of the human and macaque protein (the complete 
chimpanzee protein is currently not available). In addition, both human and mouse matriptase-2 
localise efficiently to the cell surface in cells transiently transfected with the corresponding 
expression constructs(1, 2). Other contrasting features across matriptase-2 genes are the size of 
exons 2 and 5. In human and chimpanzee, exon 2 is 203 nucleotides whereas in macaque, cow and 
dog it is 197 nucleotides and 235 nucleotides in rodents. The availability of sequence for exon 1 and 
intron A of cow and dog, will likely indicate the evolution of this, the major region of variation 
across these mammalian species. In addition, whereas exon 5 is 185 nucleotides in human, 
chimpanzee, macaque, cow and dog, this exon is 179 nucleotides in rodents. This variation leads to 
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the rodent protein being 2 residues shorter in the SEA domain-like region immediately before the 
second matriptase-2 consensus N-glycosylation site. 
 
There is also evidence that mammalian matriptase-2 genes are capable of generating multiple 
mRNA splice variants. For example in human, several splice variants are predicted to encode 
matriptase-2 isoforms; one truncated after the middle of the second CUB domain (GenBank 
accession number EAW60141) and another with amino acid insertions before both the first CUB 
domain and the protease pro-domain (GenBank accession number CAK54774). This last isoform is 
also predicted from a dog mRNA splice variant (GenBank accession number XP_850550). Another 
dog splice variant, generated by skipping exon 6, is predicted to translate a protein lacking 14 
matriptase-2 residues immediately before the first CUB domain (GenBank accession number 
XP_531743). The rat gene generates mRNA splice variants encoding the full-length protein shown 
in Figure 2 as well as an isoform lacking the transmembrane domain predicted to be a secreted 
protein (2). It will be important to determine the mechanisms regulating the generation of 
matriptase-2 splice variants and also whether protein isoforms are generated from these species. It is 
clear that several of the generated protein isoforms will be functionally different to the full-length 
protein. In particular, these include isoforms predicted to be secreted proteins and those lacking the 
serine protease catalytic domain. It will be important to determine the mechanisms regulating the 
generation of matriptase-2 mRNA splice variants and also the mechanisms controlling transcription 
of the matriptase-2 gene generally. Currently, there has been only one report of matriptase-2 gene 
regulation and this demonstrated gonadotropin mediated down-regulation of transcription in mouse 
testis Leydig cells (51). 
 
6. EXPRESSION PATTERN AND DISEASE ASSOCIATION  
The expression of matriptase-2 mRNA in adult and embryonic tissues, during embryonic 
development and in cancers is shown in Table 2. In human, mouse and rat, liver is the common site 
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of abundant matriptase-2 mRNA expression (1, 2). This pattern of expression in one or a few 
tissues, is consistent with the restricted transcription of most TTSP genes and also with the proposal 
that the encoded proteins have tissue-specific functions (4). For example, enteropeptidase 
expression is restricted to enterocytes of the proximal small intestine where it activates trypsinogen 
(52), while corin is predominantly produced by heart myocytes where it activates pro-ANP (7). 
Each of these proteolytic activation events occurs on the surface of these cells. Other TTSP also 
have restricted expression patterns including HAT which is mainly expressed in trachea (30), 
matriptase in the gastrointestinal tract and prostate (53), TMPRSS2 in prostate and colon (49, 54), 
hepsin in liver and kidney (48, 55), and DESC1 in epithelial locations (27). Accordingly, it will be 
important to determine the role of matriptase-2 on the surface of cells in the liver. 
 
Our analysis of the GenBank Unigene database indicated that human matriptase-2 mRNA is also 
expressed strongly in adrenal gland and brain with lower levels in lung, testis and uterus. 
Interestingly, the sites of highest expression in normal human tissues (liver, adrenal gland, brain and 
uterus) are also sites of high expression in cancer (Table 2). In addition, Velasco et al. have noted 
that the region containing the matriptase-2 gene is frequently altered in other human cancers, 
including insulinomas, ependymomas, and colorectal and breast carcinomas (1). Significantly, two 
other recent reports also indicate an association of matriptase-2 with breast cancer. A proteomics 
approach indicated elevated levels of matriptase-2 protein in invasive ductal breast carcinoma (56), 
while an epidemiological approach suggested that the matriptase-2 gene is associated with breast 
cancer risk in an Eastern Finnish population (57). To determine whether matriptase-2 is 
differentially expressed in these cancers, studies are needed comparing its expression in a defined 
population of matched non-diseased and cancerous samples.  
 
RT-PCR and in situ hybridization analyses provided significant insight into the cells expressing 
matriptase-2 mRNA in adult and embryonic mouse tissues (2). In adult tissues, in addition to liver, 
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kidney was also a site of high matriptase-2 mRNA expression with lower levels in uterus and much 
smaller amounts detected in many other tissues. In liver matriptase-2 mRNA was expressed by 
hepatocytes, whereas expression was consistent throughout kidney with glandular columnar 
epithelial cells the predominant site in uterus. In embryos matriptase-2 mRNA expression peaked at 
day 13.5 post coitus. In addition to high expression in liver, matriptase-2 mRNA was strongly 
detected in olfactory epithelial cells of the nasal cavity and in pharyngo-tympanic tubes. These data 
suggest roles for matriptase-2 in adult tissues as well as during embryogenesis. In addition, the 
overlapping expression of matriptase-2 and hepsin mRNA in embryonic and adult mouse suggested 
some extent of functional redundancy of these proteins. 
 
7. CONCLUSION 
Although the function of matriptase-2 is not known, a number of observations point to key roles for 
this protein in a restricted set of tissues and, potentially, in a number of cancers. These data also 
indicate that matriptase-2 will function by cleaving a limited repertoire of substrates/inhibitors and 
by interacting with other proteins via its non-catalytic domains. For example, the ability of 
matriptase-2 to cleave fibrinogen suggests that this enzyme will be involved in processes requiring 
fibrin formation such as angiogenesis (1) which is necessary for progression of several diseases 
including cancer. In addition, the abundant expression of matriptase-2 mRNA in the liver of human 
and rodents suggests that the encoded protein will function in this tissue and, if released from the 
cell surface, will also have a role as a circulating enzyme as is the case for other trypsin-like serine 
proteases involved in processes such as blood coagulation (58) and tissue remodelling in cancer 
(59,60). In fact it is possible that the cell surface location and proteolytic activity of matriptase-2 
will facilitate cancer progression as is the case for other TTSPs including hepsin (15) and matriptase 
(18).  
 
 13
It is clear that the functions of matriptase-2 in normal physiology and disease will be regulated at a 
number of levels. At the transcriptional level the matriptase-2 gene is capable of generating 
multiple splice variants, several of which, at least, will translate protein isoforms with differing 
functions. Also, the restricted expression pattern of matriptase-2 mRNA suggests that transcription 
is tightly regulated. Furthermore, it is likely that the unpaired cysteine of matriptase-2, which is 
located between the transmembrane domain and the first CUB domain, will be involved in homo- or 
hetero-meric linkages which will regulate protein function. In addition, the location of matriptase-2 
at the cell surface will provide a level of regulation by restricting access of the protease to potential 
substrates and also by requiring a mechanism, such as proteolysis, to release the protein from the 
cell surface. Release from the cell surface may also be mediated via transcriptional events which 
generate mRNA splice variants encoding a secreted form of the protein.  
 
As has been the case for other members of the TTSP family including corin (8), hepsin (15) and 
matriptase (17, 18, 61), it is likely that greatest progress on the patho-physiological roles of 
matriptase-2 will occur using either knock-out or transgenic mice. It has also been suggested that 
the overlapping expression of matriptase-2 and hepsin in mice indicates a level of functional 
redundancy which will require the careful analysis of matriptase-2 knock-out mice and, potentially, 
the generation of matriptase-2/hepsin double knock-out mice (2).  
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Table 1 – Summary of matriptase-2 database entries. 
 
Chromosome GenBank Amino
Organism Location Accession Acids
Human (Homo sapiens ) 22q12.3 NP_705837 811
Chimpanzee (Pan troglodytes ) 22 (position XR_024662 na
35944325-35945129) incomplete
Macaque (Macaca mulatta ) 10 (position XP_001085319 809
80966561-80967372)
Cow (Bos taurus ) 6 XP_871580 800
Pig (Sus scrofa ) no entry na1 na
Dog (Canis familiaris ) 10 XP_531743 786
Sheep (Ovis aries ) no entry na na
Cat (Felis catus ) no entry na na
Mouse (Mus musculus ) 15 E2 NP_082178 811
Rat (Rattus norvegicus ) 7q34 XP_235768 811
Notes: 1. na, not applicable  
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Table 2 – Matriptase-2 mRNA expression. 
 
Rat
Northern UniGene1 RT-PCR UniGene UniGene
adrenal gland nr2 31 nr na na
brain/whole brain nil 16 -/+ 0 0
colon nil 0 nr na na
head and neck nr na3 nr 69 0
heart/vascular nil 0 -/+ 80 0
intestine/GI tract4 nil 0 -/+ 0 0
kidney nil 0 +++ na 0
leukocytes/blood nil 0 nr 0 na
liver +++++ 25 +++++ 641 142
lung nil 5 -/+ 9 0
mammary gland nr 0 nr 9 na
muscle nil 0 -/+ 37 0
ovary nil 0 nr na na
pancreas nil 0 -/+ 0 0
placenta nil 0 nr na 0
prostate nil 0 nr 0 na
spleen nil 0 -/+ 10 na
stomach nil na -/+ na na
testis nil 8 nr 0 na
thymus nil 0 -/+ 0 na
uterus nr 8 ++ na na
adrenal tumor nr 78 nr na na
glioma nr 9 nr na na
liver tumor nr 22 nr na na
uterine tumor nr 22 nr na na
fetal brain nil na nr na na
fetal kidney nil na nr na na
fetal liver ++++ na nr na na
fetal lung nil na nr na na
fetus nr 9 nr na na
embryo nr 0 nr 0 0
mid-gestation embryo nr na nr 5 na
neonate nr 0 nr 36 0
juvenile nr 0 nr 20 73
adult nr 3 nr 22 0
embryo day 7.5 nr na -/+ na na
embryo day 8.5 nr na -/+ na na
embryo day 9.5 nr na -/+ na na
embryo day 10.5 nr na -/+ na na
embryo day 12.5 nr na ++ na na
embryo day 13.5 nr na +++++ na na
embryo day 15.5 nr na ++ na na
Notes: 
1. GenBank UniGene database - transcripts per million
2. nr, not reported
3. na, not available
4. GI tract, gastrointestinal tract
Human Mouse
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FIGURE LEGENDS 
Figure 1 Matriptase-2 domain structure. Features are summarised at the bottom of the panel.  
 
Figure 2 Multiple sequence alignment. Matriptase-2 protein sequences were aligned using the 
EclustalW algorithm (Australian National Genome Information Service website). The 
transmembrane domain was identified using the TMHMM algorithm and matriptase-2 sequences 
were analysed for modular protein domains using the SMART algorithm (ExPASy Proteomics 
Tools website). Underlined domains: CUB, complement protein subcomponents C1r/C1s, urchin 
embryonic growth factor and bone morphogenetic protein 1 domain; LDLR, low density lipoprotein 
receptor class A domain. A region with lower homology to sea urchin sperm protein, 
enteropeptidase, agrin (SEA) domains is underlined by a dashed line. Consensus N-glycosylation 
sites are indicated N1 to N7. Cysteines are numbered C1 to C37. The catalytic histidine, aspartate 
and serine residues necessary for serine protease activity are indicated by “H”, “D” and “S” 
respectively. The activation site is indicated by an arrow. Sequences were obtained from the 
following GenBank entries: Human NP_705837; Macaque XP_001085319; Dog XP_531743; Cow 
XP_871580; Mouse NP_082178; Rat XP_235768. 
 
Figure 3 Matriptase-2 structure. A. Protein structural features are marked in the upper panel and 
include transmembrane (black box), two CUB, three LDLR (L), activation (black oval) and 
proteolytic (boxed HDS) domains. Genomic organization is indicated in the lower panel. Coding 
and non-coding exon regions are represented by, respectively, black and white boxes. Upper exons 
1 and 2 represent the structure of the gene in higher mammals (human, chimpanzee and macaque) 
and the lower exons 1 and 2 represent the gene structure in rodents. Dotted lines indicate exons 
encoding the protein structural domains in panel A. Not to scale. B. Comparison of sizes of exons 
and introns of the matriptase-2 gene in 7 mammalian species.  
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consensus N-glycosylation site
unpaired cysteine
disulfide bond
Human ---MLLLFHSKRMPVAEAPQVAGGQGDGGDGEE-AEPEGMFKACEDSKRKARGYLRLVPLFVLLALLVLASAGVLLWYFLGY 78
Macaque ---MLLLFHSERMPVAKAPQVAGGQGDGGDGEE-AEPEGMFEAREDSKRKARGYLRLAP--LWLTLVVLTSVGVLLWYFLGY 76
Dog ------------MPMAEAPQAAGGQGDGGDGEE-AEPEGMFKATEISKRKVRDYLRLVP--LWLALVVLASVGVLLWYFLGY 67
Cow ------------MPMAKAPQAAGGQGDGGDGEE-AEPEGMFKAPKDAKRKVRDYLRLAP--LWLALVMLASVGVLLWYFLGY 67
Mouse MPRCFQLPCSTRMPTTEVPQAADGQGDAGDGEEAAEPEGKFKPPKNTKRKNRDYVRFTP--LLLVLAALVSAGVMLWYFLGY 80
Rat MPRCFQLPCSTRMPTAEVPQAAGGQGDGGDGEEAAEPEGVFKAPRNAKRKDRDYVRFTP--LLLVLAALASAGVMLWYFLGY 80
N1 C1
Human KAEVMVSQVYSGSLRVLNRHFSQDLTRRESSAFRSETAKAQKMLKELITSTRLGTYYNSSSVYSFGEGPLTCFFWFILQIPE 160
Macaque KAEVTVSQVYSGSLRVLNRHFSQDLTRRESSAFRSETAKAQKMLKELIASTRLGTYYNSSSVYSFGEGPLTCFFWFILQIPE 158
Dog KAEVTVSQVYSGSVRVLNRHFSQDLARRESSAFRSETAKAQKMLKELIASTRLGTYYNSSSVYSFGEGPLTCFFWFILQIPE 149
Cow KAEVTVSQVYSGSLRVLNRHFSQDLARRESSAFRSETAKAQKMLKELIASTPLGTYYNSSAVYSFGEGPFTCFFWFILQIPE 149
Mouse KAEVTVSQVYSGSLRVLNRHFSQDLGRRESIAFRSESAKAQKMLQELVASTRLGTYYNSSSVYSFGEGPLTCFFWFILDIPE 162
Rat KAEVTISQVYSGSLRVLNRHFSQDLARRESIAFRTETAKAQKMFQELVASTRLGTYYNSSSIYAFGEGPLICFFWFILDIPE 162
N2 N3 C2
Human HRRLMLSPEVVQALLVEELLSTVNSSAAVPYRAEYEVDPEGLVILEASVKDIAALNSTLGCYRYSYVGQGQVLRLKGPDHLA 242
Macaque HRRLMLSPEVVQALLVEELLSTVNSSAAVPYRAEYEVDPEGLVILEASVKDIAALNSTLGCYRYSYVGQGQVLRLKGPDHLA 240
Dog HRRPMLSPEVVRALLVEELLSTANSSAPAPYRAEYEVDPEGLVILEASVKDIVALNATLGCYRYSYVGQGQVLRLKGPDHLA 217
Cow HRRPMLSPDVVRALLAEELLSAVNSSAPAPYRTEYEVDPEGLVILEASVKDIVALNSTLGCYRYSYVGQGQALRLKGPDTLA 231
Mouse YQRLTLSPEVVRELLVDELLS--NSSTLASYKTEYEVDPEGLVILEASVNDIVVLNSTLGCYRYSYVNPGQVLPLKGPDQQT 242
Rat YQRLTLSPEVVRELLVGELLS--NSSALASYRTEYEVDPEGLVILEASVNDIVVLNSTLGCYRYSYVNPGQVLRLRGPDQQT 242
C3 C4 C5
Human SSCLWHLQGPKDLMLKLRLEWTLAECRDRLAMYDVAGPLEKRLITSVYGCSRQEPVVEVLASGAIMAVVWKKGLHSYYDPFV 324
Macaque SSCLWHLQGPEDLMLKLRLEWTLAECRDRLAMYDVAGPLEKRLITSVYGCSRQEPVVEVLASGAIMAVVWKKGLHSYYDPFM 322
Dog SSCLWHLQGPKDLMLKLRLEWTLAECRDRLAMYDVAGPLERRLITSVYGCSRQEPVVEVLASGAVMAVVWKKGLHSYYDPFV 299
Cow SSCLWHLQGPQDLMLKLRLEWKLADCRDRLAMYDVAGPLERRLITSVYGCSRQEPVVEVLASGAIMAVVWKKGLHSYYDPFV 313
Mouse TSCLWHLQGPEDLMIKVRLEWTRVDCRDRVAMYDAAGPLEKRLITSVYGCSRQEPVMEVLASGSVMAVVWKKGMHSYYDPFL 324
Rat TSCLWHLQGPEDLMLKVQLEWTRVDCRDRVAMYDAAGPLEKRLITSVYGCSRQEPVMEVLASGSVMAVVWKKGLHSFYDPFL 324
C6 N4 C7 C8
Human LSVQPVVFQACEVNLTLDNRLDSQGVLSTPYFPSYYSPQTHCSWHLTVPSLDYGLALWFDAYALRRQKYDLPCTQGQWTIQN 406
Macaque LSVQSVVFQACEVNLTLDDRLDSQGVLSTPYFPSYYSPRTHCSWHLTVPSLDYGLALWFDAYALRRQKYDLPCTQGQWTIQN 404
Dog LSVQPVAFQACEVNLTLEGRLEPQGVLSTPYFPSYYSPSTHCSWHLTVPSLDYGLALWFDAYALRRQKYDLPCTQGQWTIQN 381
Cow LSVQPVTIQACEVNLTLEGRLEPQGVLSTPYFPSYYSPSTHCSWHLTVPSLDYGLALWFDAYALRRQKYNMPCTQGQWTIQN 395
Mouse LSVKSVAFQDCQVNLTLEGRLDTQGFLRTPYYPSYYSPSTHCSWHLTVPSLDYGLALWFDAYALRRQKYNRLCTQGQWMIQN 406
Rat LSVKSVAFQDCQVNLTLEGRLDPQGFLRTPYYPSYYSPSTHCSWHLTVPSLDYGLALWFDAYALRRQKYNLLCTQGQWMIQN 406
C9 N5 N6 C10 C11 C12 C13 C14
Human RRLCGLRILQPYAERIPVVATAGITINFTSQISLTGPGVRVHYGLYNQSDPCPGEFLCSVNGLCVPACDGVKDCPNGLDERN 488
Macaque RRLCGLRILQPYAERIPVVATAGITINFTSQISLTGPGVRVHYGLYNQSDPCPGEFLCSVNGLCVPACDGVKDCPNGLDERN 486
Dog RRLCGLRTLQPYAERIPVVATAGITVNFTSQIPLTGPGVQVHYGLYNQSDPCPGEFLCSVNGLCVPACDGVKDCPNGLDERN 463
Cow RRLCGLRTLQPYAERIPVVASAGITINFTSQISLTGPGVQVHYSLYNQSDPCPGEFLCSVNGLCVPTCDGVKDCPNGLDERN 477
Mouse RRLCGFRTLQPYAERIPMVASDGVTINFTSQISLTGPGVQVYYSLYNQSDPCPGEFLCSVNGLCVPACDGIKDCPNGLDERN 488
Rat RRLCGFRTLQPYAERIPVVASDGITINFTSQISLTGPGVQVYYSLYNQSDPCPGEFLCSVNGLCVPACDGIKDCPNGLDERN 488
C15 C16 C17 C18 C19 C20N7 C21 C22 C23 C24 C25 C26 C27 C28
Human CVCRATFQCKEDSTCISLPKVCDGQPDCLNGSDEEQCQEGVPCGTFTFQCEDRSCVKKPNPQCDGRPDCRDGSDEEHCDCGL 570
Macaque CVCRATFQCQEDSTCISLLKVCDGQPDCLNGSDEERCQEGVPCGTFTFQCEDQSCVKKPNPQCDGRPDCRDGSDEQHCDCGL 568
Dog CVCRATFQCQEDSTCISLSRVCDRQPDCLNGSDEEHCQEGVPCGTFTFQCEDRSCVKKPNPQCDGLPDCRDGSDEQHCDCGL 545
Cow CVCRATFQCQEDSTCIPLSRVCDRQPDCLNGSDEEQCQEGVPCGTFTFRCEDHSCVKKPNPQCDGHPDCRDGSDEQHCDCGL 559
Mouse CVCRAMFQCQEDSTCISLPRVCDRQPDCLNGSDEEQCQEGVPCGTFTFQCEDRSCVKKPNPECDGQSDCRDGSDEQHCDCGL 570
Rat CVCRAMFQCQEDSTCISLPRVCDRQPDCLNGSDEEQCQEGVPCGTFTFQCEDRSCVKKPNPECDGQADCRDGSDEEHCDCGL 570
C29 C30
Human QGPSSRIVGGAVSSEGEWPWQASLQVRGRHICGGALIADRWVITAAHCFQEDSMASTVLWTVFLGKVWQNSRWPGEVSFKVS 652
Macaque QGPSSRIVGGAVSSEGEWPWQASLQVRGRHICGGALIADRWVITAAHCFQEDSMASPALWTVFLGKVWQNSRWPGEVSFKVS 650
Dog QGPSGRIVGGAVSSEGEWPWQASLQIRGRHICGGALIADRWVITAAHCFQDDSMASPALWTVFLGKVWQSSRWPGEVSFKVS 627
Cow QGPLGRIVGGAVSSEGEWPWQASLQVRGRHICGGALIADRWVITAAHCFQEESMASPALWTVFLGKVWQSSRWPGEVSFKVS 641
Mouse QGLSSRIVGGTVSSEGEWPWQASLQIRGRHICGGALIADRWVITAAHCFQEDSMASPKLWTVFLGKMRQNSRWPGEVSFKVS 652
Rat QGPSSRIVGGAMSSEGEWPWQASLQIRGRHICGGALIADRWVITAAHCFQEDSMASPRLWTVFLGKMRQNSRWPGEVSFKVS 652
H
C31 C32 C33
Human RLLLHPYHEEDSHDYDVALLQLDHPVVRSAAVRPVCLPARSHFFEPGLHCWITGWGALREGGPISNALQKVDVQLIPQDLCS 734
Macaque RLLLHPYHEEDSHDYDVALLQLDHPVVRSAAVRPVCLPARSHFFEPGLHCWITGWGALREGGPTSNALQKVDVQLIPQDLCS 732
Dog RLLLHPYHEEDSHDYDVALLQLDHPVVRSAAVRPVCLPARSHFFEPGLHCWITGWGALREGGPTSNGLQKVDVQLIPQDLCS 709
Cow RLLLHPYHEEDSHDYDVALLQLDHPVVRSATVQPICLPARSHFFEAGLHCWITGWGALREGGPTSNGLQKVDVQLIPQDLCS 723
Mouse RLFLHPYHEEDSHDYDVALLQLDHPVVYSATVRPVCLPARSHFFEPGQHCWITGWGAQREGGPVSNTLQKVDVQLVPQDLCS 734
Rat RLFLHPYHEEDSHDYDVALLQLDHPVVYSATVRPVCLPARSHFFEPGQHCWITGWGAQREGGPGSSTLQKVDVQLIPQDLCN 734
D
C34 C35 C36 C37
Human EVYRYQVTPRMLCAGYRKGKKDACQGDSGGPLVCKALSGRWFLAGLVSWGLGCGRPNYFGVYTRITGVISWIQQVVT 811
Macaque EAYRYQVTPRMLCAGYRKGKKDACQGDSGGPLVCKALSGRWFLAGLVSWGLGCGRPNYFGVYTRITGVIGWIQQVVT 809
Dog EAYRYQVTPRMLCAGYRKGKKDACQGDSGGPLVCKEPSGRWFLAGLVSWGLGCGRPNYFGVYTRITGVIGWIQQVLT 786
Cow EAYRYQVTPRMLCAGYRNGKKDACQGDSGGPLVCKEPSGRWFLAGLVSWGLGCGRPNYFGVYTRITGVIGWIQQVLT 800
Mouse EAYRYQVSPRMLCAGYRKGKKDACQGDSGGPLVCREPSGRWFLAGLVSWGLGCGRPNFFGVYTRVTRVINWIQQVLT 811
Rat EAYRYQVTPRMLCAGYRKGKKDACQGDSGGPLVCKEPSGRWFLAGLVSWGLGCGRPNFFGVYTRVTRVVNWIQQVLT 811
S
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ATG
ATG
STOP
Human Chimpanzee Macaque Cow Dog Mouse Rat
Exon 1 140 >1001 140 n/a n/a 186 184
Intron A 95 95 95 n/a n/a 3082 >4042
Exon 2 203 203 197 197 197 235 235
Intron B 4666 4666 4789 4834 3726 3730 4713
Exon 3 134 134 134 134 134 134 134
Intron C 1700 1417 1256 1410 1640 737 691
Exon 4 68 68 68 68 68 68 68
Intron D 557 556 562 551 519 516 520
Exon 5 185 185 185 185 185 179 179
Intron E 313 310 305 241 226 273 246
Exon 6 42 42 42 42 42 42 42
Intron F 5768 >6467 4534 4043 3128 4311 4709
Exon 7 205 205 205 205 205 205 205
Intron G 3158 >4028 2713 2721 1999 632 604
Exon 8 137 137 137 137 137 137 137
Intron H 1443 1442 1434 1356 1351 1240 1167
Exon 9 113 incomplete2 113 113 113 113 113
Intron I 322 incomplete 321 295 335 206 200
Exon 10 110 110 110 110 110 110 110
Intron J 9014 >9261 >9200 8427 8270 5667 5559
Exon 11 146 146 146 146 146 146 146
Intron K 426 426 445 377 360 360 320
Exon 12 99 99 99 99 99 99 99
Intron L 964 964 978 940 769 806 >959
Exon 13 114 114 114 114 114 114 114
Intron M 2499 incomplete 1527 1357 1325 1071 726
Exon 14 117 incomplete 117 117 117 117 117
Intron N 263 incomplete 272 327 277 250 249
Exon 15 169 169 169 169 169 169 169
Intron O 1139 1135 1118 1331 1308 1123 1097
Exon 16 272 272 272 272 272 272 272
Intron P 2110 2106 2022 1996 1696 1537 1532
Exon 17 137 137 137 137 137 137 137
Intron Q 587 587 581 >292 532 235 205
Exon 183 803 (159) 797 (159) 803 (159) 807 (159) 694 (159) 796 (159) 692 (159)
Total 37415 >40330 >35340 >33550 >30400 28239 30692
Notes:
1. The greater than symbol indicates that the intron has not been completely sequenced.
2. Incomplete indicates that sequence at an exon /intron junction is not available.
3. The bracketed amount is the size of the coding sequence for exon 18.
A.
B.
